diarrhea
import
caus
morbid
mortal
neonat
calv
sever
enteropathogen
associ
diarrhea
young
calv
enterotoxigen
escherichia
coli
etec
infect
common
type
colibacillosi
rise
antibiot
resist
number
medic
import
bacteri
pathogen
reviv
interest
use
bacteriophag
antibacteri
therapeut
agent
describ
result
random
placebocontrol
doubleblind
studi
design
evalu
effect
oral
bacteriophag
cocktail
fecal
e
coli
colonyform
unit
cfu
ten
calv
enrol
studi
either
bacteriophag
group
placebo
group
feed
calv
bacteriophag
treatment
group
n
receiv
total
plaqueform
unit
pfu
volum
ml
four
bacteriophag
placebo
group
n
receiv
phosphatebuff
salin
ml
fresh
fecal
sampl
blood
sampl
collect
daili
calf
analyz
bacteri
count
presenc
bacteriophag
e
coliinfect
phage
recov
phagetr
calv
concentr
pfu
per
gram
rectal
content
none
detect
serum
phage
treatment
caus
reduct
fecal
e
coli
compar
control
group
mean
log
cfu
placebotr
group
se
versu
se
phagetr
group
differ
statist
signific
diarrhea
remain
import
caus
morbid
mortal
neonat
calv
constabl
econom
loss
associ
diseas
due
result
mortal
also
retard
growth
anim
cost
veterinari
care
drug
use
treat
infect
increas
labor
involv
de
graaf
et
al
sever
enteropathogen
associ
diarrhea
neonat
calv
preval
escherichia
coli
clostridium
perfringen
salmonella
spp
cryptosporidium
spp
rotaviru
coronaviru
rel
import
vari
geograph
region
snodgrass
et
al
youni
et
al
escherichia
coli
gramneg
bacterium
normal
found
intestin
anim
although
e
coli
nonpathogen
abl
caus
intestin
extra
intestin
infect
larg
number
e
coli
present
farm
environ
result
fecal
contamin
initi
exposur
pathogen
e
coli
may
occur
contamin
calv
pen
system
infect
usual
requir
predispos
environment
factor
inadequ
transfer
passiv
immun
compromis
immun
system
infect
common
type
colibacillosi
young
anim
caus
noninvas
enterotoxigen
e
coli
etec
strain
also
lead
caus
diarrhea
among
travel
children
develop
world
nagi
feket
rise
antibiot
resist
number
medic
import
bacteri
pathogen
denou
et
al
reviv
interest
use
bacteriophag
treat
bacteri
infect
merril
et
al
phage
therapi
consid
potenti
lowcost
treatment
modal
first
implement
felix
dherel
year
ago
howev
develop
antibiot
put
halt
commerci
product
therapeut
phage
western
countri
wherea
soviet
union
enter
diseas
nosocomi
infect
burn
wound
infect
continu
treat
phage
prepar
larg
scale
appar
success
sulakvelidz
therefor
object
evalu
effect
oral
administr
bacteriophag
fecal
e
coli
cfu
addit
also
object
assess
surviv
phage
impact
oral
phage
administr
calf
health
onesid
hypothesi
oral
administr
e
coli
bacteriophag
would
caus
reduct
fecal
e
coli
cfu
random
placebocontrol
doubleblind
studi
perform
colleg
veterinari
medicin
cornel
univers
ithaca
ny
may
june
bull
calv
purchas
birth
local
dairi
farm
plu
week
age
enrol
studi
time
calv
randomli
chosen
submit
physic
examin
veterinarian
farm
commingl
transport
trailer
randomli
offload
cornel
univers
time
identif
tag
place
right
ear
anim
weigh
calv
assign
treatment
group
hous
order
remov
trailer
first
day
treatment
technic
mistak
made
one
calf
receiv
differ
code
bucket
one
assign
receiv
exclus
calf
necessari
manag
group
kept
prior
treatment
given
calf
move
initi
group
assign
group
calv
individu
hous
perman
stall
high
tile
wall
concret
floor
within
close
barn
activ
ventil
system
prevent
contact
calv
calv
fed
commerci
fat
nonmed
milk
replac
nurs
formula
nt
calf
milk
replac
land
olak
inc
kg
dri
matter
dm
per
day
split
feed
durat
studi
milk
replac
consum
within
min
fed
anim
via
esophag
tube
feeder
freechoic
water
avail
time
stall
clean
bed
daili
pine
shave
steam
clean
pressur
water
gross
manur
contamin
stall
wall
also
remov
daili
pullov
boot
water
bucket
milk
bucket
milk
bottl
thermomet
label
treatment
group
share
calv
receiv
differ
treatment
calv
enrol
studi
receiv
feed
follow
farm
manag
calf
receiv
two
feed
milk
per
day
studi
personnel
associ
calf
manag
sampl
collect
blind
treatment
treatment
vial
colorcod
laboratori
studi
member
particip
data
collect
code
broken
end
studi
prestudi
period
day
use
collect
baselin
data
fecal
e
coli
cfu
phage
cocktail
pfu
calf
health
two
day
blood
manur
sampl
collect
cfu
pfu
quantif
well
obtain
calf
health
data
calv
start
monitor
feed
intak
feed
receiv
record
visual
health
apprais
twice
daili
veterinarian
blind
treatment
alloc
feed
follow
data
record
health
score
fecal
score
weight
temperatur
calf
health
assess
visual
use
object
criteria
appetit
fecal
consist
hydrat
statu
respiratori
effort
attitud
berg
et
al
calv
would
remov
censor
studi
clinic
statu
appear
critic
point
studi
period
fortun
necessari
calf
singl
dose
flunixin
meglumin
banamin
mgml
mgkg
schere
plough
use
treat
one
calf
depress
attitud
antibiot
treatment
use
studi
period
studi
day
treatment
began
calv
bacteriophag
treatment
group
receiv
total
pfu
volum
ml
genet
distinct
bacteriophag
placebo
group
calv
receiv
placebo
ml
pb
treatment
treatment
phage
placebo
administ
morn
afternoon
ad
reconstitut
milk
replac
immedi
feed
anim
treatment
group
receiv
bacteriophag
cocktail
compound
four
bacteriophag
previous
isol
manur
lagoon
two
larg
commerci
dairi
farm
locat
near
ithaca
ny
bicalho
et
al
bacteriophag
hightit
stock
propag
purifi
follow
inoculum
overnight
cultur
propag
host
strain
e
coli
previous
isol
uterin
secret
metrit
cow
ad
ml
lb
broth
incub
h
shake
approxim
pfu
isol
bacteriophag
ad
cultur
incub
min
without
shake
sampl
incub
h
vigor
shake
concentr
phage
prepar
obtain
precipit
lb
lysat
naclpolyethylen
glycol
peg
accord
protocol
describ
sambrook
russel
solid
nacl
final
concentr
ad
sampl
stir
sampl
kept
ice
h
sampl
centrifug
g
min
remov
debri
supernat
lb
lysat
transfer
steril
flask
solid
peg
final
concentr
wv
ad
lysat
sampl
kept
ice
least
h
allow
bacteriophag
particl
precipit
precipit
bacteriophag
particl
recov
centrifug
min
resuspend
sm
buffer
largescal
hightit
stock
titrat
use
standard
overlay
techniqu
store
fresh
fecal
sampl
collect
daili
per
rectum
latex
examin
glove
store
steril
contain
sampl
kept
chill
transport
laboratori
bacteria
enumer
fecal
sampl
conduct
vortex
g
fecal
sampl
ml
pb
falcon
tube
fecal
sampl
dilut
pb
aerob
cultur
macconkey
agar
plate
h
aliquot
spiral
plate
triplic
assess
presenc
quantiti
bacteriophag
blood
blood
sampl
calf
collect
vacuum
contain
refriger
process
centrifug
min
ml
plasma
transfer
eppendorf
tube
serial
dilut
prepar
ad
ml
phage
solut
steril
broth
sm
buffer
phage
serial
dilut
calf
quantifi
microdrop
triplic
plate
examin
h
number
pfu
determin
assess
presenc
quantiti
fecal
bacteriophag
daili
fecal
sampl
collect
laboratori
stool
sampl
g
homogen
pb
g
nacl
g
trypton
per
liter
final
volum
ml
stool
sampl
centrifug
min
falcon
tube
filter
millex
prefilt
follow
minisart
filter
subsequ
sampl
store
serial
dilut
prepar
spot
test
done
lb
agar
petri
dish
gl
agar
overlaid
ml
lb
top
agar
gl
petri
dish
enumer
calf
divid
quadrant
dilut
dilut
dilut
dilut
dilut
ten
microlit
dilut
appli
three
spot
clockwis
distribut
quadrant
plate
top
agar
plate
e
coli
bacteria
solidifi
phage
propag
count
indic
strain
e
coli
amount
phage
estim
consid
last
dilut
dilut
phage
caus
visibl
bacteri
lysi
equival
virion
gener
amplifi
phage
plaqu
differ
appear
dilut
wellsepar
plaqu
chosen
count
posit
stool
sampl
evalu
effect
ph
bacteriophag
viabil
sampl
isol
phage
mix
seri
tube
contain
sm
buffer
ph
valu
rang
incub
h
titrat
doublelay
agar
plate
method
evalu
effect
bacteriophag
therapi
quantiti
lactoseneg
fecal
bacteria
also
quantiti
fecal
bacteriophag
two
repeat
measur
anova
analys
perform
use
mix
procedur
sa
sa
institut
inc
cari
nc
outcom
variabl
log
cfu
fecal
lactoseneg
bacteria
log
pfu
fecal
bacteriophag
outcom
variabl
longitudin
collect
repeat
measur
error
term
model
impos
firstord
autoregress
covari
structur
appropri
account
withincalf
correl
repeat
measur
phage
treatment
caus
numer
reduct
fecal
e
coli
compar
control
mean
log
cfu
placebotr
group
se
versu
se
phagetr
group
differ
statist
signific
p
fig
addit
log
cfu
phagetr
group
decreas
quickli
first
phage
treatment
administ
indic
potenti
treatment
effect
nevertheless
despit
known
vitro
antimicrobi
efficaci
phage
cocktail
e
coli
strain
bicalho
et
al
repeat
oral
applic
high
titer
phage
cocktail
significantli
reduc
fecal
e
coli
cfu
howev
statist
power
studi
limit
given
calv
enrol
evalu
suscept
phage
acid
vitro
experi
carri
phage
expos
rang
ph
valu
dilut
show
higher
lytic
action
among
serial
dilut
made
laboratori
rel
viabil
estim
compar
phage
titer
acid
sm
buffer
neutral
sm
buffer
ph
phage
nonviabl
ph
effect
higher
ph
ph
viabil
phage
use
studi
evid
fig
present
studi
fecal
phage
titer
estim
spot
dilut
tube
onto
bacteri
lawn
e
coli
presenc
phage
dilut
sampl
determin
occurr
plaqu
clear
zone
bacteri
lawn
bacteriophag
recov
treat
group
studi
day
h
first
phage
treatment
fig
e
coliinfect
phage
recov
phagetr
calv
concentr
pfug
fecal
matter
studi
day
bacteriophag
detect
fece
control
calv
studi
day
mean
phage
titer
reach
approxim
pfug
studi
day
mean
phage
titer
decreas
pfug
studi
day
final
day
studi
mean
phage
titer
pfu
rozema
et
al
report
signific
decreas
e
coli
oral
bacteriophagetr
adult
cattl
compar
steer
receiv
treatment
rectal
applic
conclud
longer
retent
time
experienc
oral
administ
phage
within
digest
tract
digesta
present
liquid
solid
phase
increas
opportun
phage
interact
target
e
coli
cell
replic
therebi
increas
phage
popul
size
likelihood
infect
addit
e
coli
cell
factor
interfer
phagebacterium
interact
includ
inoculum
size
time
manner
administr
presenc
antiphag
immun
respons
appear
phageresist
mutant
smith
et
al
anoth
relev
factor
elucid
author
acid
stomach
content
time
phage
administr
especi
import
oral
phage
treatment
result
evalu
suscept
phage
acid
equival
smith
et
al
report
mild
acid
b
ph
b
present
abomasum
content
calv
shortli
milk
feed
littl
harm
effect
oral
administ
phage
wherea
high
acid
ph
b
predomin
partial
empti
stomach
lethal
phage
denou
et
al
use
mice
found
lower
phage
titer
cecum
larg
intestin
compar
initi
amount
phage
ad
drink
water
author
mention
acid
mous
stomach
ph
possibl
explan
phage
loss
howev
find
bruttin
suggest
consider
phage
stabil
gastrointestin
transit
human
author
abl
detect
phage
fecal
sampl
volunt
ingest
phage
drink
water
concentr
pfuml
constitut
phage
cocktail
use
e
coli
strain
isol
bovin
uteri
host
bicalho
et
al
one
could
argu
better
result
might
obtain
fecal
e
coli
isol
use
host
predatorprey
relationship
phage
target
bacteria
exemplifi
work
tanji
et
al
studi
popul
e
coli
wastewat
stream
increas
popul
bacteriophag
activ
e
coli
host
specif
phage
depend
abil
recogn
specif
cellsurfac
receptor
tanji
et
al
strain
specif
could
explan
observ
stool
sampl
control
group
present
phage
environment
origin
host
use
phage
enumer
e
coli
strain
isol
uteru
metrit
dairi
cow
summari
bacteriophag
administ
oral
recov
high
number
fecal
sampl
collect
h
administr
therebi
indic
surviv
low
ph
abomasum
addit
numer
decreas
cfu
lactoseneg
fecal
bacteria
observ
phagetr
group
howev
differ
statist
signific
bacteriophag
surviv
vitro
exposur
ph
level
low
high
complet
absenc
phage
observ
ph
side
effect
oral
phage
therapi
observ
health
studi
calv
throughout
studi
period
studi
oral
bacteriophag
therapi
warrant
field
trial
use
larger
number
anim
potenti
nonantibiot
therapi
newborn
colibacillosi
actual
potenti
conflict
interest
includ
financi
person
relationship
peopl
organ
within
three
year
begin
submit
work
could
inappropri
influenc
perceiv
influenc
work
